Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
112actual
Sites
1
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-23 | actual | When the study began enrolling |
| Primary completion | 2026-01-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-26 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Myeloid Leukemia (AML)
Intervention
- Drug: Oral azacitidine
Primary outcomes
what the primary-completion date above is the date OFParticipant real-world relapse-free survival (rw-RFS)
measured Up to date of documented relapse or death assessed up to 41 months
Participant overall survival (OS)
measured Up to date of documented death assessed up to 41 months
Participant relapsed-free survival (RFS)
measured From date of achieved complete remission up to 41 months
Participant overall survival (OS) from the time of complete remission achievement
measured From date of achieved complete remission up to 41 months
Participant relapse rate
measured 6 and 12 months
Time to treatment discontinuation (TTD)
measured Up to 41 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed